Adage Capital Partners
AVIR icon

Adage Capital Partners’s Atea Pharmaceuticals AVIR Stock Holding History

Adage Capital Partners’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-422,210
Closed -$14.8M – 1024
2021
Q3 		$14.8M Sell
422,210
-475,000
-53% -$13.2M 0.03% 569
2021
Q2 		$19.3M Sell
897,210
-797,209
-47% -$24M 0.04% 486
2021
Q1 		$105M Hold
1,694,419
– – 0.21% 108
2020
Q4 		$70.8M Buy
+1,694,419
New +$54.6M 0.15% 146

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

Adage Capital Partners's AVIR Position: Q4 2021 in Review

Adage Capital Partners sold out of Atea Pharmaceuticals (AVIR) in Q4 2021, closing a stake of 422,210 shares — an estimated $14.8M sold.

Adage Capital Partners first reported a position in AVIR in Q4 2020 and held it in 4 quarters. The position peaked at $105M in Q1 2021. 143 funds tracked by Wall St. Rank hold AVIR as of Q4 2021.

  • Adage Capital Partners reported no remaining Atea Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Adage Capital Partners sold 422,210 Atea Pharmaceuticals shares in Q4 2021, an estimated $14.8M.
  • Adage Capital Partners first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 4 quarters.
  • Adage Capital Partners's Atea Pharmaceuticals position peaked at $105M in Q1 2021.
  • 143 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2021.

Based on Adage Capital Partners's 13F filing for Q4 2021, filed 14 Feb 2022.